Suzanne Forry, Ph.D.

Dr. Suzanne Forry attained her Ph.D. in Anatomy and Cell Biology from the University of Pennsylvania School of Medicine. She joined the National Institutes of Health (NIH) in 2004 as a Scientific Review Official at the Center for Scientific Review. Prior to joining NIH, Dr. Forry directed the gene therapy oncology programs at Genetic Therapy, Incorporated, a wholly-owned subsidiary of Novartis, where her laboratory focused on cancer immunotherapy. Dr. Forry joined the Preclinical Therapeutics Grants Branch at the National Cancer Institute (NCI) as a Program Director in 2008 where she manages a portfolio of research grants spanning from drug discovery through pre-clinical studies supporting future clinical trials. She is currently a point person for a funding opportunity on cancer drug screening, and leads the Glioblastoma Therapeutics Network (GTN), an effort to move novel therapeutic agents for adult GBM from preclinic to early stage clinical trials. Dr. Forry's portfolio spans all cancer types. Areas of focus are strategies to inhibit mutant KRAS, and mechanisms of action and resistance to targeted therapies with particular focus on lung and brain cancers.